Clinical Trial

Restoring Bile Acid Homeostasis Via Lifestyle Adjustments to Prevent the Development of Liver Cancer

Study acronym: RE-BALANCE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, non-randomized interventional study nested within the existing ELEGANCE cohort. Patients eligible for the RE-BALANCE study will be selected from the ELEGANCE cohort based on predefined high-risk criteria, specifically a low 12-non-hydroxy/12-hydroxy bile acid ratio indicative of elevated hepatocarcinogenic risk. The study comprises Baseline Assessments (Visit 1), Intervention Visits (Visit 2-8), and Follow-up Assessments (Visit 9-11).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-31; most recent amendment 2026-05-12.
Trial Details
NCT Number NCT07111130
Lead Sponsor National Cancer Centre, Singapore
Collaborators: Perspectum, BUZUD Pte Ltd, Asian Microbiome Library (AMiLi) Pte Ltd
Conditions Liver Diseases
Enrollment 90 participants
Start Date 2026-07
Primary Completion 2027-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-15